Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Molecular Cancer Therapeutics

Volumn 8, Issue 2, 2009, Pages 324-332

  Squires, Matthews ^a   Feltell, Ruth E ^a   Wallis, Nicola G ^a   Lewis, E Jonathan ^a   Smith, Donna Michelle ^a   Cross, David M ^a   Lyons, John F ^a   Thompson, Neil T ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AT 7519; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; N (4 PIPERIDINYL) 4 (2,6 DICHLOROBENZOYLAMINO) 1H PYRAZOLE 3 CARBOXAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; HUMANS; MICE; MICE, NUDE; PIPERIDINES; PYRAZOLES; SMALL MOLECULE LIBRARIES; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60849123760     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0890     Document Type: Article

References (37)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
3. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
4. Morgan D. Principles ofCDK regulation. Nature 1995;374:131 -4.
5. Dohadwala M, Da Cruz E, Silva E, et al. Phosphorylation and inactivation ofprotein phosphatase 1 by cyclin-dependent kinases. Proc Natl Acad Sci U S A 1994;91:6408 - 12.
6. Kwon Y, Lee S, Choi Y, Greengard P, Nairn AC. Cell cycle-dependent phosphorylation ofmammalian protein phosphatase 1 by cdc2 kinase. Proc Natl Acad Sci U S A 1997;94:2168 - 73.
7. Brown VD, Phillips RA, Gallie BL. Cumulative effect of phosphorylation ofpRb on regulation ofE2F activity. Mol Cell Biol 1999;19:3246 - 56.
8. 1 Cell 1999;98:859-69.
9. Zhao J, Dynlacht B, Imai T, Hori T, Harlow E. Expression of NPAT, a novel substrate ofcyclin E-CDK2, promotes S-phase entry. Genes Dev 1998;12:456 - 61.
10. Zhao J, Kennedy B, Lawrence BD, et al. NPAT links cyclin E-CDK2 to the regulation of replication-dependent histone gene transcription. Genes Dev 2000;14:2283 - 97.
11. 1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 2000;20:3497 - 509.
12. 1 phase progression. J Biol Chem 2002;277:31263 - 9.
13. Pinhero R, Liaw P, Bertens K, Yankulov K. Three cyclin dependent kinases preferentially phosphorylate different parts of the C-terminal domain ofthe large subunit ofRNA polymerase II. Eur J Biochem 2004;271:1004 - 14.
14. Garriga J, Grana X. Cellular control ofgene expression by T-type cyclin/CDK9 complexes. Gene 2004;337:15-23.
15. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms ofaction ofthe anti-cancer drug flavopiridol. Genome Biol 2001;2:1 - 11.
16. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. CDK2 knockout mice are viable. Curr Biol 2003;13:1775-85.
17. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45.
18. Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31.
19. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell 2003;114:431 - 43.
20. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases CDK4 and CDK6. Cell 2004;118:493-504.
21. Malumbres M, Barbacid M. Mammalian cyclin dependent kinases. Trends Biochem Sci 2005;30:630-41.
22. Cai D, Latham VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66:9270-80.
23. 1 arrest with inhibition ofcyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
24. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003;2:S84-95.
25. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
26. Christian BA, Grever MR, Byrd JC, Lin TS. Flavopiridol in the treatment ofchronic lymphocytic leukemia. Curr Opin Oncol 2007;19:573-8.
27. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
28. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclindependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008;26:59-65.
29. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008;29:16 - 21.
30. BlundellTL,JhotiH,AbellC. High through put crystallography for lead discovery in drug design. Nat Rev Drug Discov 2002;1:45 - 54.
31. Wyatt PG, Wood head AJ, Berdini V, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide, (AT7519), a novel cyclin dependent kinase inhibitor using fragment based X-ray crystallography and structure based drug design. J Med Chem 2008;51:4986-99.
32. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
33. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties ofthe cyclin dependent kinase inhibitor CYC202 (R-roscovi-tine). Int J Cancer 2002;102:463-8.
34. Patel V, Senderowicz AM, Pinto D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998;102:1674-81.
35. DePinto W, Chu X, Yin X, et al. In vitro and in vivo activity of R457:a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644-58.
36. 1-2 arrest, shows anti-tumour activity on cisplatin-resistant cells and significant in vivo efficacy in tumour models. Mol Cancer Ther 2007;6:926-34.
37. Payton M, Chung G, Yakowec P, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer res 2006;66:4299-308.